SAN DIEGO--(BUSINESS WIRE)--Genome Insight, a clinical laboratory, is proud to announce its accreditation by the College of American Pathologists (CAP) for its whole genome sequencing services. The CAP accreditation, effective January 2024, solidifies Genome Insight's status as a trusted provider of high quality and reliable genomic services.
Since the opening of the laboratory in San Diego in September 2022, Genome Insight has been dedicated to advancing precision medicine through the comprehensive analysis of tumor and normal samples using whole genome sequencing. The CAP accreditation is a significant accomplishment that highlights the laboratory's high quality and accuracy of the laboratory’s genomic services.
Stephanie Ferguson, Chief Clinical Operations Officer of Genome Insight, Inc., emphasizes the importance of whole genome sequencing in advancing precision medicine. "Whole genome sequencing is revolutionizing precision medicine and leading to significant breakthroughs in personalized therapeutics," said Ferguson. "At Genome Insight, we prioritize the highest standards to achieve comprehensive analysis without compromising on rigorous assay standards."
CAP accreditation is recognized as the gold standard in laboratory accreditation and signifies a laboratory's commitment to meeting the highest quality standards in patient care. By successfully meeting the CAP's rigorous requirements, Genome Insight has demonstrated its commitment to excellence in genomic testing. This accreditation strengthens the confidence of physicians, healthcare providers, and patients in the accuracy and reliability of the laboratory's whole genome sequencing services.
Genome Insight is committed to improving personalized patient care by continually advancing its genomic offerings with advanced technologies and experienced professionals. The CAP accreditation serves as a testament to the laboratory's ongoing efforts to provide exceptionally high quality genomic testing services to positively transform patient care.
About Genome Insight
Genome Insight, Inc. is a global company, with headquarters in San Diego, California. The company was brought to fruition by physicians with a common vision to deliver unparalleled bioinformatics that merge whole-genome and patient data to deliver first-in-class research and discovery, precision diagnostics and treatments. The company operates a CLIA-certificated laboratory and having an effort for best environment to analysis. The company’s mission is to improve how patients are diagnosed and treated by unlocking the full potential of personalized genomic data. To learn more, please visit https://genomeinsight.net.
